Home Natera Inc.

Natera Inc.

Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program Reports Natera

ProActive Study will follow 3,000 kidney transplant patients over a three to five year period to examine the utility of the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test to accurately identify organ rejection.

Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer Shows Benefits According to a New Study

A new, peer-reviewed case study published in JCO Precision Oncology1 demonstrates the unique ability of Signatera technology to detect esophageal cancer recurrence almost one year before current standards of care, using a simple blood draw to monitor for traces of circulating tumor DNA (ctDNA). This report builds upon a fast-growing body of scientific evidence behind the Signatera test across multiple cancer types.

National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer

The trial is organized by the NCC and national in scope, and it is expected to include approximately 1500 patients from over 100 cancer centers across Japan.

Natera Announces Pricing of Follow-On Offering

Closing of the offering is expected to occur on October 21, 2019, subject to customary closing conditions.

Panorama NIPT Achieves 2 Million Test Milestone

The Panorama test has been extensively validated in 18 peer-reviewed published­ clinical studies involving more than 170,000 patients.

Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay

2/22/19: Natera reports the analytical validation was based on the analysis of 1,064 replicate samples from both related/non-related donor-recipient pairs.